Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Operating Expenses (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Operating Expenses for 12 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 17.28% year-over-year to $4.4 million, compared with a TTM value of $21.1 million through Sep 2025, down 29.45%, and an annual FY2024 reading of $23.4 million, down 8.94% over the prior year.
  • Operating Expenses was $4.4 million for Q3 2025 at Lisata Therapeutics, down from $4.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $12.5 million in Q4 2023 and bottomed at $4.4 million in Q3 2025.
  • Average Operating Expenses over 3 years is $6.4 million, with a median of $5.9 million recorded in 2024.
  • Peak annual rise in Operating Expenses hit 3.55% in 2024, while the deepest fall reached 52.47% in 2024.
  • Year by year, Operating Expenses stood at $12.5 million in 2023, then crashed by 52.47% to $5.9 million in 2024, then fell by 25.8% to $4.4 million in 2025.
  • Business Quant data shows Operating Expenses for LSTA at $4.4 million in Q3 2025, $4.9 million in Q2 2025, and $5.8 million in Q1 2025.